Cargando…
Updates in therapeutic drug monitoring in inflammatory bowel disease
Biologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn’s disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medi...
Autores principales: | Lodhia, Nilesh, Rao, Shanti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185221/ https://www.ncbi.nlm.nih.gov/pubmed/35800180 http://dx.doi.org/10.3748/wjg.v28.i21.2282 |
Ejemplares similares
-
Endoscopy in inflammatory bowel disease: Role in diagnosis, management, and treatment
por: Spiceland, Clayton M, et al.
Publicado: (2018) -
Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
por: Albader, Farah, et al.
Publicado: (2021) -
Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape
por: LeBlanc, Jean-Frédéric, et al.
Publicado: (2019) -
Pregnancy and medications for inflammatory bowel disease: An updated narrative review
por: Akiyama, Shintaro, et al.
Publicado: (2023) -
Novel drug delivery systems for inflammatory bowel disease
por: Yasmin, Farah, et al.
Publicado: (2022)